This has potentially direct clinical relevance: While combination treatment of BRAF/MEK inhibitors and immune checkpoint inhibition have led to durable responses and improved survival in metastatic and BRAF inhibitor‐resistant melanoma, a subgroup of patients still relapses and develops therapy resistance (Gide et al, 2018). Here, BRAF is linked to melanoma.